Primary Sclerosing Cholangitis (PSC) Overview

Primary sclerosing cholangitis (PSC) is a rare chronic liver disease that causes progressive inflammation and scarring of the bile ducts, leading to bile flow obstruction and liver damage1 . It most commonly affects adults between 30 and 40 years of age and predominantly males2 . PSC is closely linked with inflammatory bowel disease (IBD), especially ulcerative colitis, with about 70% of patients having concomitant IBD3 . The disease often progresses slowly but can result in serious complications such as liver failure and bile duct cancers2 4.

Types of PSC

PSC is classified into several types based on the location and extent of bile duct involvement and associated conditions.

Classic PSC, also known as large-duct PSC, involves chronic inflammation and fibrosis affecting both the intrahepatic (inside the liver) and extrahepatic (outside the liver) bile ducts2 . This form accounts for approximately 90% of PSC cases5 . The inflammation causes multifocal strictures (narrowing) and segmental dilations of the bile ducts, impairing bile flow and leading to cholestasis and liver injury2 . Classic PSC has a relatively poorer prognosis compared to other types and is the most commonly diagnosed form2 .

Small-duct PSC is characterized by inflammation limited to the small intrahepatic bile ducts, with normal cholangiographic imaging of the larger bile ducts2 . It represents about 5% of PSC patients5 . Diagnosis often requires liver biopsy to detect typical histological features since imaging may appear normal2 . Small-duct PSC generally has a more favorable prognosis than classic PSC but may progress to large-duct PSC over time5 2.

Some patients exhibit features of both PSC and autoimmune hepatitis (AIH), an immune-mediated liver disease targeting hepatocytes6 . This overlap syndrome involves inflammation of both small and large bile ducts2 . The prognosis of PSC with autoimmune hepatitis overlap is intermediate, worse than small-duct PSC but better than classic PSC2 . Management may require addressing both autoimmune and cholestatic components of the disease.

PSC Symptoms and Signs

Symptoms of PSC vary widely and often depend on the stage of the disease.

Common Symptoms

Many patients with PSC are asymptomatic at diagnosis, with approximately 50% showing no symptoms initially5 . Early symptoms, when present, are often vague and nonspecific, including:

• Fatigue, a frequent complaint in PSC patients7 5
• Abdominal discomfort or pain, especially in the right upper quadrant7 5
• Diarrhea, often related to associated inflammatory bowel disease5
• Pruritus (itching), a common cholestatic symptom7 8
• Jaundice (yellowing of the skin and eyes), resulting from bile duct obstruction5 9

Bile Duct Infection Symptoms

As PSC progresses and bile duct strictures worsen, patients may develop bacterial cholangitis (infection of the bile ducts), which can cause:

• Fever and chills5 8
• Right upper quadrant abdominal pain5
• Jaundice5
• Recurrent episodes of infection due to impaired bile flow5

Advanced Symptoms

In advanced PSC, complications of liver cirrhosis and liver failure may manifest, including:

• Enlarged liver (hepatomegaly) and spleen (splenomegaly) 10
• Ascites (fluid accumulation in the abdomen) 10
• Weight loss and night sweats8
• Portal hypertension symptoms such as variceal bleeding10

PSC Causes and Risk Factors

The exact cause of PSC remains unknown, but it is believed to involve a combination of genetic, immune, and environmental factors.

Risk Factors

• Genetic predisposition: Variants in HLA genes increase susceptibility to PSC, often interacting with environmental triggers6 .
• Immune-mediated mechanisms: PSC is considered an immune-mediated disease with autoimmune features targeting bile ducts2 6.
• Inflammatory bowel disease: About 70% of PSC patients have concomitant IBD, mainly ulcerative colitis, which is strongly associated with PSC development3 11.
• Male sex: PSC predominantly affects males, with a male-to-female ratio of approximately 2:12 .
• Age: Most commonly diagnosed in adults aged 30 to 40 years2 .
• Family history: Having first-degree relatives with PSC increases individual risk, indicating genetic susceptibility6 .
• Other autoimmune diseases: PSC is associated with autoimmune conditions such as type 1 diabetes and autoimmune thyroiditis2 .
• Environmental factors: Exposure to infections or toxins may trigger immune responses in genetically predisposed individuals2 8.

Diagnosing Primary Sclerosing Cholangitis

Diagnosis of PSC involves a combination of clinical evaluation, laboratory tests, imaging, and sometimes liver biopsy.

• Laboratory tests: Typically show a cholestatic pattern with elevated alkaline phosphatase and bilirubin levels2 .
• Imaging: Magnetic resonance cholangiopancreatography (MRCP) is the gold standard non-invasive imaging modality to visualize multifocal bile duct strictures and dilations characteristic of PSC2 12.
• Endoscopic retrograde cholangiopancreatography (ERCP): Used for diagnosis and therapeutic interventions, especially for dominant strictures2 13.
• Percutaneous transhepatic cholangiography (PTC): Alternative imaging when MRCP or ERCP are inconclusive or not feasible2 .
• Ultrasound and CT scans: Can detect biliary dilatation and liver abnormalities but are less specific than MRCP2 .
• Liver biopsy: Mainly used to diagnose small-duct PSC or exclude other liver diseases; not routinely required for classic PSC2 14.

Diagnosis also requires exclusion of secondary causes of sclerosing cholangitis, such as bile duct injury, infections, or IgG4-related cholangiopathy2 15.

PSC Treatment Options

Currently, there is no curative medical therapy for PSC. Treatment focuses on symptom control, managing complications, and liver transplantation for advanced disease.

Minimally Invasive Procedures

• Endoscopic interventions: ERCP-guided balloon dilation and stenting are used to treat dominant strictures and improve bile flow2 13.
• Stenting or balloon dilation: Maintain bile duct patency and relieve obstruction2 .
• Antibiotics: Indicated for bacterial cholangitis complicating PSC2 .
• Beta-blockers: Used to manage portal hypertension in advanced PSC2 .

Medications

• Pruritus management: Cholestyramine is commonly used to alleviate itching in cholestatic liver diseases2 .
• Rifampin: Used off-label to reduce pruritus associated with cholestasis2 .
• Naltrexone: May be effective in treating pruritus in PSC2 .
• Ursodeoxycholic acid: Has been used in PSC treatment, but its benefit remains controversial and is not universally recommended2 .

Surgery

• Liver transplantation: The only known curative treatment for advanced PSC with liver failure or complications such as cholangiocarcinoma2 16.
• Approximately 40% of PSC patients eventually require liver transplantation, which significantly improves survival16 .
• Post-transplant survival rates are approximately 85% at 1 year and 70% at 5 years16 .
• Disease recurrence after transplantation occurs in a significant minority of patients2 .

PSC Prevention Strategies

Currently, there is no known way to prevent PSC due to its unclear etiology2 . However, patients are advised to:

• Avoid alcohol consumption to support liver health2 10.
• Maintain a balanced and healthy diet2 .
• Avoid raw or undercooked animal products and unpasteurized dairy to reduce infection risk17 .
• Supplement fat-soluble vitamins (A, D, E, K) to prevent deficiencies caused by cholestasis2 .
• Supplement vitamin D and calcium to prevent metabolic bone disease2 .

Conditions Related to PSC

PSC is associated with several related conditions and complications:

• Inflammatory bowel disease (IBD): Present in about 70% of PSC patients, mainly ulcerative colitis and Crohn's disease5 .
• Metabolic bone disease: Osteoporosis affects approximately 15% of PSC patients due to malabsorption and vitamin deficiencies2 .
• Gallbladder pathology: Gallstones occur in up to 25% of patients; gallbladder cancer risk is increased2 .
• Malignancies: PSC significantly increases the risk of cholangiocarcinoma (bile duct cancer) in 10-20% of patients and colorectal cancer, especially in those with IBD2 18.
• Dominant biliary strictures: Common complications causing bile duct obstruction2 .
• Bacterial cholangitis: Frequent infectious complication due to bile duct strictures and impaired bile flow2 .

Living With Primary Sclerosing Cholangitis

Living with PSC involves managing symptoms, monitoring for complications, and addressing quality of life issues.

• Fatigue and pruritus are common and can impact daily functioning7 .
• Patients often require vitamin supplementation to address fat-soluble vitamin deficiencies2 .
• Regular screening for colorectal cancer and cholangiocarcinoma is recommended due to increased risk18 .
• Psychosocial support and counseling are important to help patients cope with the chronic nature and uncertainty of PSC19 .
• Peer support groups and online communities provide valuable resources and social support19 .

“Primary sclerosing cholangitis and the management of uncertainty and complexity require a multidisciplinary approach to improve patient outcomes and quality of life.”

— Arndtz K., Hirschfield G.M. 19

PSC Frequently Asked Questions

What is the typical prognosis for PSC?
Median survival from diagnosis to liver transplantation or death ranges from 10 to 20 years without transplantation4 16.

Is there a cure for PSC?
Currently, there is no curative medical therapy; liver transplantation is the only known cure for advanced disease2 16.

Can PSC recur after liver transplantation?
Yes, PSC recurrence occurs in a significant minority of patients after transplantation2 .

What are the main complications of PSC?
Complications include cholangiocarcinoma, colorectal cancer, metabolic bone disease, bacterial cholangitis, and liver failure2 18.

How is PSC diagnosed?
Diagnosis relies on cholestatic liver enzyme patterns and characteristic bile duct changes on MRCP imaging, with liver biopsy reserved for small-duct PSC or unclear cases2 .